Emerging Implant Technologies (EIT) acquired a portfolio of 22 issued and pending patents covering a complete range of 3D printed expandable spinal fusion cages for vertical and lateral expansion. First products based on these patents will launch in 2018.
The patents address multiple geographies, including the U.S. and Europe, and are based on “living hinge” designs by Morgan P. Lorio, M.D.
EIT’s additively-manufactured Cellular Titanium scaffold structures have a porosity of 80% and pore size of 650 μm, and are designed to mimic trabecular bone structure and obviate the need for bone graft. EIT received its first U.S. FDA 510(k) product clearance just last month for a suite of cervical and lumbar cages, and the company began marketing the devices immediately. Outside of the U.S, EIT’s products have been used in >10,000 cases in >15 countries, including Australia, France, Germany, Korea and the Netherlands.
Meanwhile, competitor K2M has acquired exclusive license to a portfolio of 17 issued and pending patents for expandable interbody fusion devices, which will be developed using its proprietary Lamellar 3D Titanium Technology™.
Emerging Implant Technologies (EIT) acquired a portfolio of 22 issued and pending patents covering a complete range of 3D printed expandable spinal fusion cages for vertical and lateral expansion. First products based on these patents will launch in 2018.
The patents address multiple geographies, including the U.S. and Europe, and are based...
Emerging Implant Technologies (EIT) acquired a portfolio of 22 issued and pending patents covering a complete range of 3D printed expandable spinal fusion cages for vertical and lateral expansion. First products based on these patents will launch in 2018.
The patents address multiple geographies, including the U.S. and Europe, and are based on “living hinge” designs by Morgan P. Lorio, M.D.
EIT’s additively-manufactured Cellular Titanium scaffold structures have a porosity of 80% and pore size of 650 μm, and are designed to mimic trabecular bone structure and obviate the need for bone graft. EIT received its first U.S. FDA 510(k) product clearance just last month for a suite of cervical and lumbar cages, and the company began marketing the devices immediately. Outside of the U.S, EIT’s products have been used in >10,000 cases in >15 countries, including Australia, France, Germany, Korea and the Netherlands.
Meanwhile, competitor K2M has acquired exclusive license to a portfolio of 17 issued and pending patents for expandable interbody fusion devices, which will be developed using its proprietary Lamellar 3D Titanium Technology™.
Copy to clipboard 
